UNSPSC 51141508: Ethosuximide

This classification denotes an anticonvulsant agent with the molecular formula C7H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5SEH9X1D1D, chemically known as 2,5-pyrrolidinedione, 3-ethyl-3-methyl- but generally known as ethosuximide, which bears US NIH Compound Identifier 3291. European Medicines Agency schedules Ethosuximide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07282MIG.

UNSPSC 51141508 Ethosuximide is a Commodity code that covers anticonvulsant medications and related pharmaceutical products sourced by state and local health agencies. Recent state and local opportunities tagged to this code reveal a wider procurement scope spanning naloxone distribution systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceutical supply agreements rather than ethosuximide specifically. State health and human services departments, county health systems, and multistate cooperative purchasing alliances are the primary issuing bodies, with activity driven by community health initiatives, pharmacy benefit program modernization, and consolidated pharmaceutical procurement across multiple jurisdictions.

The most active recent opportunities originate in Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB (IFB60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, under a two-year contract with one-year renewal option. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, a preliminary market-intelligence phase preceding formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, spanning participating state and local government facilities in Minnesota and Oregon. The MMCAP procurement requires vendors to work through three authorized wholesalers, certify cGMP and Drug Supply Chain Security Act compliance, maintain $5 million commercial general liability insurance, and accept a 3 percent administrative fee on all purchases.